ClinicalTrials.gg
CompletedNCT02354950Updated Aug 5, 2020

A Study to Evaluate Pharmacokinetic (PK) and Safety of GSK1265744 in Subjects With Hepatic Impairment and Control Healthy Volunteers

A Phase 1 interventional study of GSK1265744 30mg in HIV Infections, sponsored by ViiV Healthcare. Completed at 3 sites in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-08-05.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2016, 10 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing cabotegravir in HIV Infections — 4 open to participants now, 13 under way, 8 of them phase 3. cabotegravir · HIV Infections.

Enrollment
31st of 36
16 · median 200
Started
2015
with 2 others
Phase 1
10 of 36
none open now
Registered
7th of 36
by date
Lead sponsor
24 of 36
ViiV Healthcare

Among the 36 studies testing cabotegravir in HIV Infections, this one is the 31st largest by enrollment, is one of 3 that started in 2015, is one of 10 in phase 1, and was the 7th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

4 of the 36 studies testing cabotegravir in HIV Infections are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About cabotegravir

cabotegravir: first FDA approval 2021 (VOCABRIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing cabotegravir in HIV Infections, or all of them as a file.
02

Study summary

This will be a Phase 1, open-label, parallel group, two-part, single-dose adaptive study in adults with moderate and mild (if needed) hepatic impairment and matched, healthy control subjects with normal hepatic function. In Part 1, healthy control subjects (n=8) matched to subjects with moderate (n=8) hepatic impairment will be enrolled. If the geometric mean total plasma area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time (AUC[0-infinity]) of GSK1265744 is increased by >2-fold in moderately impaired subjects relative to matched controls, Part 2 will be conducted to evaluate GSK1265744 PK in subjects with mild hepatic impairment (n=8) and matched, control subjects (n=8). All subjects will receive a single 30 milligram (mg) oral dose of GSK1265744. The primary objective of the study is to compare plasma PK parameters of GSK1265744 in subjects with hepatic impairment to healthy controls matched in gender, age, and body mass index (BMI).

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • GSK1265744
  • healthy controls
  • pharmacokinetic
  • Hepatic Impairment
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hepatic Impaired Subjects (Cohort 1 and 3)
  • Between 18 and 70 years of age

Part 1 subjects with Moderate Hepatic Impairment Only (Cohort 1):

  • Subject is considered to have moderate hepatic impairment (of any etiology) and has been clinically stable for at least 1 month prior to screening. Having moderate hepatic impairment with a score of 7-9 and previous confirmation of liver cirrhosis.

Part 2 subjects with Mild Hepatic Impairment Only (Cohort 3):

  • Subject is considered to have mild hepatic impairment (of any etiology) and has been clinically stable for at least 1 month prior to screening. Having mild hepatic impairment, with a Child-Pugh score of 5-6 and previous confirmation of chronic liver disease.
  • Supplemental inclusion criteria for all hepatically impaired subjects: Chronic (>6 months), stable (no acute episodes of illness within the previous 1 month prior to screening due to deterioration in hepatic function) hepatic impairment due to any etiology. Subjects must also remain stable throughout the Screening period. - Body weight >=50 kilogram (kg) and within the range 19 - 41 kilogram per meter square (kg/m\^2) (inclusive).
  • Male or female: Capable of giving signed which includes compliance with the requirements and restrictions listed in the consent form and the protocol.

Inclusion Criteria for Healthy Subjects (Cohorts 2 and 4):

  • Healthy control subjects will be matched for age +/-10 years to subjects in the respective hepatic impairment cohort but must also remain in the age range between 18 and 70 years inclusive, at the time of signing the informed consent.
  • Healthy as determined by the investigator or medically qualified designee. Healthy control subjects will be matched for BMI +/-25 percent to subjects in the respective hepatic impairment cohort but must also remain in the range of: Body weight >=50 kg and BMI within the range 19 - 41 kg/m\^2 (inclusive)
  • Male or female: Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the consent form and in the protocol.

Exclusion criteria

Exclusion Criteria:

  • Exclusion Criteria for Hepatic Impaired Subjects (Cohort 1 and 3):
  • Presence of Grade 3 or 4 elevations in (AST), alanine aminotransferase (ALT), or ; interval (QTc) > 480 milliseconds (msec);
  • The subject's systolic BP is outside the range of 90-160 millimeter of mercury (mmHg), or diastolic BP is outside the range of 45-95mmHg or heart rate is outside the range of 50-100 beats per minute (bpm) for female subjects or 45-100 bpm for male subjects
  • Evidence of previous myocardial infarction in the past 12 months or any active cardiovascular disease that, in the opinion of the investigator, could interfere with the safety of the subject.
  • Any clinically significant conduction abnormality
  • Any significant arrhythmia.
  • Non-sustained or sustained ventricular tachycardia.
  • Evidence of recent infection with and/or within preceding 6 months. Subjects with chronic Hepatitis B or C (duration>6 months)
  • Subjects with a pre-existing condition (except hepatic impairment) interfering with normal gastrointestinal anatomy or motility that could interfere with the absorption, metabolism, and/or excretion of the study drugs. Subjects with a history of cholecystectomy and inflammatory bowel disease should be excluded.

Subjects with a history of peptic ulceration or pancreatitis within the preceding 6 months of screening should be excluded.

  • Subjects with previous gastrointestinal (GI) surgery (except appendectomy more than three months prior to study) should be excluded.
  • Subjects with (CLCR) \<=60 milliliter per minute (mL/min) (calculated by the Modification of Diet in Renal Disease [] equation).
  • Subjects with advanced ascites (Grade 3 or 4).
  • Subjects with encephalopathy as judged by the investigator or significant Central Nervous System (CNS) disease.
  • History of gastric or esophageal variceal bleeding within the past 6 months;
  • Subjects with Transjugular Intrahepatic Portosystemic Shunt (TIPS) placement;
  • Presence of hepatopulmonary or hepatorenal syndrome;
  • Presence of primarily cholestatic liver diseases;
  • History of liver transplantation;
  • Subjects with signs of active infection;
  • Subjects with unstable cardiac function or subjects with hypertension whose blood pressure is not controlled;
  • Diabetic subjects whose diabetes is not controlled;
  • Subjects with any other medical condition (other than hepatic impairment) which, in the judgment of the investigator and medical monitor, could jeopardize the integrity of the data derived from that subject or the safety of the subject;
  • Subjects requiring any concurrent prohibited medication listed in study protocol;
  • Subjects receiving lactulose who are medically unable to halt lactulose administration from 8 hours before dosing with study drug to 4 hours after dosing with study drug;
  • Subjects with a change in dose regimen of medically required medication within the 2 weeks prior to dosing;
  • History of regular alcohol consumption within 6 months of the study;
  • Inability or unwillingness to comply with lifestyle and/or dietary restrictions outlined in protocol;
  • History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates their participation. ;
  • Unwillingness or inability to follow the procedures outlined in the protocol;
  • A positive pre-study drug/alcohol screen;
  • A positive test for (HIV) antibody;
  • Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period;
  • Subject's with a count \<50,000 x 10\^9 per liter (/L) of blood who have had a major bleeding episode within the past 6 months;
  • Subjects with electrolyte imbalance;
  • The subject has participated in a clinical trial and has received an product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
  • Exclusion Criteria for Healthy Subjects (Cohorts 2 and 4):
  • ALT and bilirubin >1.5x (ULN) (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35 percent). A single repeat is allowed for eligibility determination;
  • Current or chronic history of liver disease;
  • QTc > 450 msec;
  • Exclusion criteria for screening as per study protocol;
  • Systolic BP outside the range of 90-145 mmHg, or diastolic BP outside the range of 45-95 mmHg or heart rate outside the range of 50-100 bpm for female subjects or 45-100 bpm for male subjects;
  • Evidence of previous myocardial infarction;
  • Any clinically significant conduction abnormality;
  • Any significant arrhythmia.
  • Non-sustained or sustained ventricular tachycardia;
  • Subjects with a pre-existing condition interfering with normal gastrointestinal anatomy or motility that could interfere with the absorption, metabolism, and/or excretion of the study drugs. Subjects with a history of cholecystectomy and inflammatory bowel disease. Subjects with a history of peptic ulceration or pancreatitis within 6 months of screening. Subjects with previous GI surgery (except appendectomy more than three months prior to study).
  • The use of any concurrent prohibited medications as outlined in study protocol.
  • History of regular alcohol consumption within 6 months of the study,
  • Inability or unwillingness to comply with lifestyle and/or dietary restrictions outlined in study protocol.
  • History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates their participation.
  • Unwillingness or inability to follow the procedures outlined in study protocol.
  • Presence of hepatitis B surface antigen (HBsAg) (or positive hepatitis B core antibody with negative hepatitis B surface antibody) or positive hepatitis C antibody test result.
  • A positive pre-study drug/alcohol screen.
  • A positive test for HIV antibody.
  • Where participation in the study would result in donation of blood or blood products in excess of 500 mL within 56 days.
  • The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Part 1 Cohort 1 (Moderate hepatic impairment subjects)

    Subjects with moderate hepatic impairment will receive GSK1265744 30mg as a single oral dose in the fasted state followed by pharmacokinetic sampling for total concentrations of GSK1265744 in plasma

    Drug: GSK1265744 30mg

  • Experimental
    Part 1 Cohort 2 (Healthy control subjects)

    Healthy control subjects will receive GSK1265744 30mg as a single oral dose in the fasted state followed by pharmacokinetic sampling for total concentrations of GSK1265744 in plasma

    Drug: GSK1265744 30mg

  • Experimental
    Part 2 Cohort 3 (Mild hepatic impairment subjects)

    Subjects with mild hepatic impairment will receive GSK1265744 30mg as a single oral dose in the fasted state followed by pharmacokinetic sampling for total concentrations of GSK1265744 in plasma

    Drug: GSK1265744 30mg

  • Experimental
    Part 2 Cohort 4 (Healthy control subjects)

    Healthy control subjects will receive GSK1265744 30mg as a single oral dose in the fasted state followed by pharmacokinetic sampling for total concentrations of GSK1265744 in plasma

    Drug: GSK1265744 30mg

Interventions

  • GSK1265744 30mg tablets are white to almost white coated oval tablets. All subjects will receive GSK1265744 30mg as a single oral dose in the fasted state followed by PK sampling.

06

What researchers measure

Primary outcomes

  1. Plasma area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time [AUC(0-infinity)] following a single oral dose of GSK1265744

    Plasma PK samples (2 mL of blood per sample) will be collected to measure GSK1265744 at the following time points: pre-dose (within 15 minutes prior to dose), 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 120, 168 hours post dose

    Time frame: Pre-dose (within 15 minutes prior to dose), 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 120, 168 hours post dose (Day 8)

  2. Maximum observed concentration (Cmax) following a single oral dose of GSK1265744

    Plasma PK samples (2 mL of blood per sample) will be collected to measure GSK1265744 at the following time points: pre-dose (within 15 minutes prior to dose), 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 120, 168 hours post dose

    Time frame: Pre-dose (within 15 minutes prior to dose), 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 120, 168 hours post dose (Day 8)

Secondary outcomes

  1. Unbound concentration and unbound fraction in plasma of GSK1265744 at 2 and 24 hours post dose

    Blood samples will be collected to measure bound and unbound plasma GSK1265744 concentrations at 2 and 24 hours post dose

    Time frame: Up to 24 hours post dose (Day 2)

  2. Composite of PK parameters including AUC(0-t), %AUCex, C24, t1/2, CL/F, tlag, tmax, and Vz/F following a single oral dose of GSK1265744

    PK parameters including plasma area under the concentration-time curve from time zero (pre-dose) to last time of quantifiable concentration \[AUC(0-t)\], percentage of AUC(0-infinity) obtained by extrapolation (%AUCex), concentration observed at 24-hours post dose (C24), apparent terminal phase half-life (t1/2), apparent clearance (CL/F), lag time before observation of drug concentrations (tlag), time of occurrence of Cmax (tmax) and apparent terminal phase volume of distribution (Vz/F) following a single oral dose of GSK1265744

    Time frame: Pre-dose (within 15 minutes prior to dose), 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 120, 168 hours post dose (Day 8)

  3. Adverse events (AEs) assessment

    An AE is any untoward medical occurrence in a subject or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product

    Time frame: Up to Day 14

  4. Composite of Clinical laboratory parameters including hematology, and clinical chemistry

    Assessment of Laboratory parameters will include hematology, and clinical chemistry

    Time frame: Up to Day 14

  5. Electrocardiogram (ECG) monitoring

    12-lead ECGs will be performed with the subject in a semi-supine position having rested in this position for at least 10 minutes beforehand

    Time frame: Up to Day 2

  6. Composite of Vital signs assessments will include measurement of temperature, systolic and diastolic blood pressure, heart rate and respiratory rate

    Vital signs will be measured in semi-supine position after 10 minutes rest and will include temperature, systolic and diastolic blood pressure (BP), heart rate (HR) and respiratory rate

    Time frame: Up to Day 14

07

Study locations

3 sites
  • GSK Investigational Site
    Lakewood, Colorado 80228, United States
  • GSK Investigational Site
    Orlando, Florida 32809, United States
  • GSK Investigational Site
    Minneapolis, Minnesota 55404, United States
08

References and documents

Publications

  • Shaik JSB, Ford SL, Lou Y, Zhang Z, Bakshi KK, Tenorio AR, Trezza C, Spreen WR, Patel P. A Phase 1 Study to Evaluate the Pharmacokinetics and Safety of Cabotegravir in Patients With Hepatic Impairment and Healthy Matched Controls. Clin Pharmacol Drug Dev. 2019 Jul;8(5):664-673. doi: 10.1002/cpdd.655. Epub 2019 Feb 27. PubMed 30811880 ↗

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2015 to primary completion in Sep 2016, 14 months.

Of 74 industry-sponsored phase 1 interventional studies under HIV Infections, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 18. This study's 14 months is above that.

Counting every sponsor, half of 165 studies reached it within 19 months; a quarter within 7 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2015
First posted
Feb 3, 2015
StartActual
Jun 22, 2015
Primary completionActual
Sep 16, 2016
CompletionActual
Sep 16, 2016
Last update
Aug 5, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02354950
Lead sponsor
ViiV Healthcare
Collaborators
GlaxoSmithKline
Responsible party
Sponsor
First posted
Feb 3, 2015
Start date
Jun 22, 2015
Primary completion
Sep 16, 2016
Completion
Sep 16, 2016
Last update
Aug 5, 2020

Study contacts

GSK Clinical Trials
study director · ViiV Healthcare

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cabotegravir

Start the discussion